JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences today announced that Luveniq (LX211, oral voclosporin) and its potential as a first-in-class treatment to reduce both active inflammation and disease recurrence in uveitis is being highlighted this week in a series of presentations at the 10th Congress of the International Ocular Inflammation Society (IOIS) in Prague, Czech Republic. Aspects of the Phase 3 LUMINATE clinical trial program for LX211 will be presented by principal investigators for the three-trial program, conducted in North America, Europe and India. Uveitis, the 4th leading cause of blindness, is a group of autoimmune diseases characterized by chronic inflammation of the eye. If approved by the relevant regulatory authorities LX211 has the potential to become the first oral therapy specifically approved for uveitis in most markets.
